Nadofaragene firadenovec-vncg (Adstiladrin®) is an intravesical nonreplicating adenoviral vector-based gene therapy indicated in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors. This review provides nursing considerations regarding nadofaragene firadenovec, including proper storage and handling, administration protocols, monitoring for adverse events, appropriate disposal, and patient education.
No takes yet. Share an insight, caveat, or question.
Sutton et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: